Intrepid’s team of attorneys and technologists have a long history of working with stakeholders throughout the legal, financial and pharmaceutical industries. A key source of our success is our ability to foster a quick turnaround time that is consistent with our clients’ goals. We are able to effectively leverage our team’s personal and technical expertise to obtain the results you need within a budget that is on average 30% lower by industry standards and is consistent with your expectations.
Our Managed Document Review team is a seamless blend of talent and technology resulting in a unified workflow producing high-quality and consistent work-product.
We do this by:
A key focus of Intrepid’s Managed Review offering is the Pharmaceutical Industry – specifically litigation stemming from Drug Price Competition and the Patent Term Restoration Act (aka the Hatch-Waxman Act). We bring extensive experience and a familiarity with the key components of the pharmaceutical industry and comfort with its terminology, which means not having to explain to our reviewers what terms such as Paragraph III, IV, FTF, FTM, NDA, ANDA and API mean. Our practice focuses on representing both generic and brand pharmaceutical companies.
Our Pharmaceutical Review team has years of Hatch-Waxman experience with a deep bench of attorneys holding science and chemistry backgrounds. Our reviewers have completed anywhere from 40 to 100+ Hatch-Waxman reviews. As these cases may become global in nature, we are also able to provide clients with multi-lingual reviews as well.